Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.
/ 186 items
#XY Analyst Up/Down↓
Morgan Stanley Sees Big Potential in Kalaris’ Eye Drug TH103
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.
Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Analysts Abandon Replimune: Stock Drops Sharply After Second FDA Rejection
Replimune shares plunged after the FDA issued a second rejection for its skin cancer drug RP1, prompting multiple analyst downgrades.
Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.